证券代码：300869 证券简称：康泰医学 公告编号：2025-074 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、康医转债（债券代码：123151）转股期限为 2023 年 1 月 9 日至 2028 年 6 月 30 日。 一、可转债基本情况 （一）可转债发行上市情况 经中国证券监督管理委员会《关于同意康泰医学系统（秦皇岛）股份有限公司 向不特定对象发行可转换公司债券注册的批复》(证监许可〔2022〕960 号)同意，公 司于 2022 年 7 月 1 日向不特定对象发行 7,000,000 张可转换公司债券，每张面值为 100 元，按面值发行，募集资金总额人民币 700,000,000.00 元。发行方式采用向股权 登记日收市后中国证券登记结算有限责任公司深圳分公司登记在册的发行人原股东 优先配售，原股东优先配售后余额部分（含原股东放弃优先配售部分）通过深圳证 券交易所（以下简称"深交所"）交易系 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-09-30 | 300869 | 康泰医学 | 13.50 | 14.82 | 200.07 机构专用 | | 中信证券股份有限 公司唐山大里北路 | | | | | | | | | 证券营业部 | | 2025-09-30 | 300869 | 康泰医学 | 13.50 | 22.00 | 297.00 广发证券股份有限 | | 中信证券股份有限 | | | | | | | 公司广州临江大道 | | 公司唐山大里北路 | | | | | | | 证券营业部 | | 证券营业部 | 9月30日，康泰医学大宗交易成交36.82万股，成交额497.07万元，占当日总成交额的7.53%，成交价13.5 元，较市场收盘价16.37元折价17.53%。 ...

Core Insights - The Hong Kong stock market is experiencing a significant surge in refinancing activities, driven by ample liquidity, valuation recovery, and corporate strategic expansion needs [1][4][5] Group 1: Refunding Scale - Hong Kong listed companies have raised over 280 billion HKD through various refinancing methods this year, marking a year-on-year increase of over 400% compared to 2022 [1][4] - The total amount raised has already surpassed the entire annual figure for 2024, which was 990.73 billion HKD [4] - Placement of shares has become the primary method for refinancing, accounting for 87.81% of the total, with 249.5 billion HKD raised through this method [4] Group 2: New Economy Enterprises - New economy enterprises are leading the refinancing trend, with BYD raising 43.38 billion HKD, marking the largest equity refinancing project in the global automotive industry in the past decade [6][7] - Xiaomi Group follows closely with 42.6 billion HKD raised, surpassing its total fundraising since its 2019 IPO and setting a record for Chinese tech hardware companies in overseas equity refinancing [7] - Other tech companies like Horizon Robotics and WuXi AppTec have also raised significant amounts, focusing on sectors such as biomedicine and artificial intelligence [7] Group 3: International Capital Involvement - The current refinancing wave has seen unprecedented participation from international institutional investors, including GIC and Al-Futtaim family office [9][10] - BYD's placement attracted numerous top long-term investors, with Al-Futtaim investing 3.5 billion HKD as a strategic investor [9] - Notable long-term funds like Wujin Capital have been actively investing in various companies, indicating strong international interest in the Hong Kong market [10]

证券代码：300869 证券简称：康泰医学 公告编号：2025-072 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司（以下简称"公司"）第四届董事会 第二十三次会议通知于 2025 年 9 月 16 日以邮件方式向各位董事发出，会议于 2025 年 9 月 26 日以现场会议方式在公司会议室召开。会议由公司董事长胡坤先 生召集并主持，应出席会议的董事 5 人，实际出席会议的董事 5 人，公司高级管 理人员列席了会议。本次会议的召集、召开及表决，符合《中华人民共和国公司 法》和《康泰医学系统（秦皇岛）股份有限公司章程》（以下简称"《公司章程》"） 的规定，会议合法有效。 二、董事会会议审议情况 审议通过《关于不向下修正"康医转债"转股价格的议案》 截至 2025 年 9 月 26 日，康泰医学系统（秦皇岛）股份有限公司股票已出现 任意连续三十个交易日中至少有十五个交易日的收盘价低于"康医转债"当期转 股价格的 85%的情形，触发"康医转债"转股价格向下修正条款。 综合考虑公司的基本情况、市场环境、股价走势等诸多因素，以及对公司长 期稳健发展与内在价值的信心，为维护全体投资者的利 ...

特别提示： 1、截至 2025 年 9 月 26 日，康泰医学系统（秦皇岛）股份有限公司（以下 简称"公司"）股票已出现任意连续三十个交易日中至少有十五个交易日的收盘 价低于"康医转债"当期转股价格的 85%的情形，触发"康医转债"转股价格向 下修正条款。 证券代码：300869 证券简称：康泰医学 公告编号：2025-073 债券代码：123151 债券简称：康医转债 康泰医学系统（秦皇岛）股份有限公司 关于不向下修正"康医转债"转股价格的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2、2025 年 9 月 26 日，公司召开第四届董事会第二十三次会议，审议通过 了《关于不向下修正"康医转债"转股价格的议案》，公司董事会决定本次不向 下修正"康医转债"转股价格，且在未来六个月内（即 2025 年 9 月 27 日至 2026 年 3 月 26 日），如再次触发"康医转债"转股价格的向下修正条款，亦不提出 向下修正方案。自 2026 年 3 月 27 日起算，若再次触发"康医转债"转股价格的 向下修正条款，届时公司董事会将再次召开会议决定是否行使"康 ...

Group 1 - In August, the total electricity consumption in China reached 10,154 billion kWh, a year-on-year increase of 5.0% [3] - The electricity consumption by the primary industry was 164 billion kWh, up 9.7% year-on-year; the secondary industry consumed 5,981 billion kWh, also up 5.0%; the tertiary industry saw a consumption of 2,046 billion kWh, increasing by 7.2% [3] - Cumulative electricity consumption from January to August was 68,788 billion kWh, a year-on-year growth of 4.6% [3] Group 2 - The Ministry of Industry and Information Technology reported that by the end of August, the total number of fixed broadband internet access users reached 689 million, with a net increase of 18.85 million users since the end of last year [4] - Users with internet access speeds of 100 Mbps and above accounted for 95.2% of total users, while those with speeds of 1,000 Mbps and above reached 233 million, representing 33.9% of total users [4] Group 3 - The State Administration for Market Regulation held discussions with Huo La La to ensure compliance with antitrust laws and promote fair market competition [4] - The National Internet Information Office took action against the Toutiao platform for failing to manage content responsibly, leading to penalties and required corrections [4][5] - The OECD projected a global economic growth rate of 3.2% for 2025, an increase of 0.3 percentage points from previous forecasts [4] Group 4 - Tianpu Co. announced that its stock would be suspended for further investigation due to a 15 consecutive trading limit increase [7] - Haili Co. refuted rumors regarding shell mergers and asset injections [7] - Guiguan Network denied rumors of a significant computing power collaboration with Huawei Cloud [8]

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - 康泰医学 has recently obtained the CE certification for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which is expected to positively impact the company's future operations [1] Group 1 - The products CMS1700B and CMS1700C have received CE certification from DNV Product Assurance AS [1] - The CE certification signifies that the products meet relevant EU requirements [1] - The actual sales performance of the products will depend on future market promotion efforts, and the impact on the company's future revenue remains unpredictable [1]

Core Viewpoint - Kangtai Medical (300869) has recently obtained CE certification for its color Doppler ultrasound diagnostic systems (CMS1700B, CMS1700C), indicating compliance with EU regulations and market entry eligibility, which will positively impact the company's future operations [1] Group 1 - The CE certification was issued by DNV Product Assurance AS, confirming that the products meet relevant EU requirements [1] - The certification allows the company to access the European market, enhancing its growth opportunities [1] - The positive implications for the company's future operations are highlighted, suggesting potential revenue growth and market expansion [1]

Core Viewpoint - 康泰医学 has recently obtained the CE certificate for its Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), indicating compliance with EU standards and market entry eligibility, which is expected to positively impact the company's future operations [1]. Company Summary - The product, Color Doppler Ultrasound Diagnostic System (CMS1700B, CMS1700C), has received certification from DNV Product Assurance AS [1]. - The CE certification signifies that the product meets the relevant EU requirements, allowing for access to the European market [1]. - This development is anticipated to have a beneficial effect on the company's future business operations [1].